Is kisspeptin-10 approved or legal?

Kisspeptin-10 is not approved as a drug in any jurisdiction; it is investigational with ongoing clinical trials. It is not specifically listed on the WADA prohibited list by name, though WADA's S2 category covers substances with similar pharmacological action to prohibited peptide hormones; users in competitive sport should consult current WADA guidance. It is sold and used strictly as a research compound.

What does kisspeptin-10 do?

It binds GPR54/KISS1R receptors on hypothalamic GnRH neurons, triggering pulsatile GnRH release, which then stimulates LH and FSH from the pituitary, and ultimately testosterone (men) or oestradiol/progesterone (women) from the gonads. Loss-of-function GPR54 mutations in humans abolish puberty entirely, confirming the pathway is essential for reproductive axis function.

What is kisspeptin-10's half-life and why does it matter?

Approximately 4 minutes in human plasma (IV). This is very short — Kp-10 is undetectable by around 10 minutes. Clinical research protocols therefore use continuous IV infusion (typically 1.5 μg/kg/h for 9–12 hours) or frequent dosing rather than single bolus injections for sustained effects. Community subcutaneous protocols face different bioavailability and absorption dynamics not studied in published literature.

What is the human evidence?

Multiple clinical pharmacology studies have been published, primarily from Imperial College London. These demonstrate dose-dependent LH and testosterone rises in healthy men, phase-dependent LH responses in women, and restoration of gonadotropin pulsatility in patients with hypogonadotropic hypogonadism or hyperprolactinemia-induced amenorrhea. These are small, short-duration academic studies — not Phase 3 trials. No approved indication exists.

Is kisspeptin-10 safe?

Short-term clinical pharmacology studies in more than 150 combined human exposures have reported no serious adverse events and stable safety monitoring parameters. Mild events (nausea, headache) were rare and comparable to placebo frequency. Long-term safety, effects with chronic use, or safety of community subcutaneous protocols have not been studied. It is not recommended for unsupervised human use.

How does kisspeptin-10 compare to kisspeptin-54?

Both isoforms are GPR54 agonists with identical binding pharmacology at the receptor. Kp-54 has a plasma half-life of approximately 32 minutes versus approximately 4 minutes for Kp-10, and penetrates the blood-brain barrier far more effectively, directly activating a much higher proportion of GnRH neurons after peripheral dosing. Kp-54 is more potent per mole in vivo for this reason. Kp-10's short half-life makes it more tractable for controlled research protocols but may limit subcutaneous utility.

Hormonal

Kisspeptin-10

Also known as: Kp-10, Metastin 45-54, KISS1(112-121), Kisspeptin-10 amide, Metastin decapeptide

The C-terminal decapeptide of kisspeptin, acting as a potent GPR54/KISS1R agonist that stimulates GnRH pulsatility and downstream sex hormone release; supported by multiple...

Last updated July 11, 2026

Buy Kisspeptin-10

Overview

Kisspeptin-10 (Kp-10) is the 10-amino acid C-terminal fragment of kisspeptin (the protein product of the KISS1 gene, also historically called metastin), spanning residues 112–121 of the full 145-residue precursor. It is the shortest kisspeptin isoform that retains full agonist activity at the GPR54 receptor (also known as KISS1R). All kisspeptin isoforms (Kp-54, Kp-14, Kp-13, Kp-10) share the same C-terminal RF-amide motif required for GPR54 binding; Kp-10 is the minimal pharmacophore. Kisspeptin signalling through GPR54 on hypothalamic GnRH neurons is not merely modulatory but obligatory for reproductive axis function: loss-of-function mutations in GPR54 in humans cause absent puberty and idiopathic hypogonadotropic hypogonadism (IHH) with near-complete absence of LH and FSH. This established the kisspeptin/GPR54 system as an essential gatekeeper of the hypothalamic-pituitary-gonadal (HPG) axis. Kp-10 has been studied in a meaningful number of human clinical pharmacology studies — primarily at the Imperial College London group (Dhillo, Murphy, Jayasena and colleagues) — demonstrating dose-dependent LH, FSH, and sex hormone responses in healthy men and women (in the appropriate hormonal milieu), and restoration of gonadotropin pulsatility in patients with IHH and hyperprolactinemia-induced amenorrhea. Despite substantial human pharmacology data, Kp-10 is not approved as a drug in any jurisdiction. It remains investigational, with ongoing clinical trials. It is sold and discussed as a research compound only. This entry summarises available evidence for scientific reference and is not medical advice.

How it works

Kisspeptin-10 binds GPR54 (KISS1R), a class A GPCR expressed on GnRH-secreting neurons in the hypothalamic arcuate nucleus and anteroventral periventricular nucleus. GPR54 couples to Gq/11, activating phospholipase C to generate IP3 and DAG, raising intracellular calcium and activating PKC. This depolarises GnRH neurons, triggering pulsatile GnRH release into the hypothalamo-hypophysial portal circulation. GnRH then acts at pituitary gonadotroph cells to stimulate LH and FSH synthesis and secretion. LH drives testosterone production in Leydig cells (males) and oestradiol/progesterone synthesis in ovarian theca and granulosa cells (females); FSH supports spermatogenesis (males) and follicular maturation (females). The kisspeptin/GPR54 axis also integrates steroid hormone feedback: oestradiol and testosterone regulate kisspeptin neuron activity, explaining why gonadal steroid milieu (menstrual cycle phase, sex, hypogonadal state) determines the magnitude of Kp-10 responses in clinical studies. Kp-10's extremely short plasma half-life (~4 minutes in humans) means its GPR54 stimulation is transient; clinical protocols use infusion or frequent bolus injection to sustain GnRH pulsatility. Compared to the longer isoform Kp-54 (~32 min half-life), Kp-10 has very limited capacity to cross the blood-brain barrier and directly activate GnRH neurons when administered peripherally, which partially explains Kp-54's greater in vivo potency per mole at the hypothalamic level.

Researched effects

Clinical Stimulates dose-dependent LH and FSH release in healthy men and in women in appropriate hormonal phases
Clinical Increases testosterone in healthy men following IV bolus or infusion
Clinical Restores pulsatile LH secretion and sex hormone levels in patients with hypogonadotropic hypogonadism due to NKB pathway mutations
Clinical Reactivates the hypothalamic-pituitary-ovarian axis in women with hyperprolactinemia-induced amenorrhea
Clinical Increases LH pulse frequency with sustained IV infusion in men
Preclinical Enhances libido and sexual desire (studied via GPR54-mediated mesolimbic pathway effects)
Anecdotal Restores testosterone levels and reproductive hormone axes in hypogonadal male research contexts

Evidence levels: Clinical (human trials) · Preclinical (animal/lab) · Anecdotal (community-reported).

Dosing reference

For research reference only — not a recommendation.

Clinical / studied dosing

No regulatory-approved clinical dose exists; Kp-10 is investigational. Human clinical studies have used: IV bolus: 0.3–10 nmol/kg or approximately 1 μg/kg (optimal LH response in men at ~1 μg/kg; above 3 μg/kg the response shows an inverted-U pattern with reduced LH). IV infusion: 1.5–4 μg/kg/h for 9–22.5 hours; 1.5 μg/kg/h for 12 hours is the most consistently used protocol across published IHH and amenorrhea studies. LH pulse frequency and sex hormone levels both increase significantly at this dose in multiple trials. SC bolus: tested at doses up to 10 nmol/kg; response is smaller and more variable than IV owing to lower bioavailability and slower absorption relative to the 4-minute half-life. Across published studies no serious adverse events have been reported in any dosing group. These are research doses from academic clinical pharmacology units; no approved commercial dosing protocol exists.

Community-reported dosing (anecdotal)

Anecdotal and research-reference only; not medical advice or instruction. Community protocols are sparse and inconsistent compared to other research peptides, reflecting the absence of widespread bodybuilding use. Reported community use focuses primarily on potential testosterone or libido enhancement in men, with anecdotal subcutaneous injection protocols typically in the range of 50–100 mcg per dose, one to several times per week. Some protocols describe use as a natural testosterone support compound. These ranges are not drawn from any human safety or efficacy study and should be treated as entirely speculative reference information.

Half-life: Approximately 4 minutes in human plasma following IV administration, based on pharmacokinetic data from published clinical studies. Kp-10 is undetectable in plasma by approximately 10 minutes post-IV bolus. This is markedly shorter than the related isoform Kp-54, which has a plasma half-life of approximately 32 minutes. The short half-life reflects rapid proteolytic degradation and underlies the need for infusion protocols in clinical research. SC bioavailability is lower and absorption slower. In rat studies, Kp-10 exhibits temperature-dependent degradation in vitro (half-life approximately 1.7 minutes at 37°C), highlighting stability and handling requirements for research use.
Routes: subcutaneous, intravenous

Safety & side effects

Published human clinical pharmacology studies involving multiple dosing protocols and more than 150 cumulative human exposures have reported no serious adverse events. Monitored parameters including blood pressure, heart rate, oxygen saturation, liver function, renal function, electrolytes, and haemoglobin remained stable across all published studies. Infrequently reported mild adverse events from the kisspeptin literature (not always Kp-10-specific): nausea in one of fifteen subjects in one SC-route study; headache at frequency comparable to placebo in one trial. These are isolated observations rather than consistent signals. Theoretical considerations: (1) GPR54 is expressed in some peripheral tissues beyond the hypothalamus, including the placenta, liver, and certain cancer cell lines; KISS1 was originally identified as a metastasis-suppressor gene (hence the alias metastin), and kisspeptin signalling may have anti-proliferative effects in some tumour types — though this does not establish safety concerns for short-term administration at research doses; (2) chronic supraphysiological GPR54 stimulation could theoretically desensitise the HPG axis over time (analogous to GnRH agonist downregulation), though published short-course studies show no such desensitisation. Kisspeptin-10 is not on the current WADA prohibited list as a specifically named substance at the time of available information; however, WADA's S2 category (Peptide Hormones) prohibits any substance with similar pharmacological action, and its effect on endogenous LH and testosterone could potentially raise concerns in competitive sport contexts. Users should consult current WADA guidance. Kp-10 is not an approved drug and is not recommended for human use outside monitored research settings.

Research summary

Kisspeptin-10 has an unusually solid human clinical pharmacology foundation for a research peptide, largely owing to the systematic work of the Imperial College London neuroendocrinology group. The mechanistic basis is unambiguous: GPR54 loss-of-function mutations abolish puberty and gonadotropin secretion in humans (Tena-Sempere, Hum Reprod Update 2006), placing Kp-10/GPR54 as obligatory for HPG axis function. Multiple published human studies confirm dose-dependent LH and testosterone responses to Kp-10 in healthy men, with an optimal IV bolus dose of approximately 1 μg/kg (George et al., JCEM 2011). Sexual dimorphism is real: women in the follicular phase do not respond to Kp-10 at doses up to 10 nmol/kg, but women in the preovulatory/periovulatory phase with high oestradiol priming do show LH responses (Jayasena et al., JCEM 2011). Continuous infusion at 1.5 μg/kg/h for 9–12 hours increases LH pulse frequency in men and restores gonadotropin pulsatility in patients with IHH secondary to NKB pathway mutations (Young et al., Neuroendocrinology 2013) and in hyperprolactinemia-induced amenorrhea (Millar et al., J Endocrine Soc 2017). The pharmacokinetic distinction between Kp-10 and Kp-54 is well characterised: Kp-10's 4-minute plasma half-life versus Kp-54's ~32-minute half-life translates into profoundly different CNS exposure — Kp-54 activated 22% of GnRH neurons in mouse brain vs. essentially zero for peripheral Kp-10 — explaining Kp-54's greater in vivo potency per mole despite similar GPR54 binding affinity (d'Anglemont de Tassigny et al., PLoS ONE 2017). Limitations: all published therapeutic-application studies are small (n=4–25), of short duration (single session to 12 hours), and academic. No Phase 2 or Phase 3 trial has established an approved therapeutic protocol. No long-term data on HPG axis effects, desensitisation, or safety beyond the study sessions exist. Community use (subcutaneous protocols for testosterone enhancement) is speculative, unsupported by controlled data, and uses routes with uncertain pharmacokinetics relative to the IV protocols in published literature. Overall: Kp-10 is mechanistically well understood, has genuine short-term human efficacy data for acute HPG axis stimulation, and displays a favourable short-term safety profile in monitored research settings. It remains investigational, with no approved indication, and the large gap between IV infusion research protocols and community subcutaneous self-administration practices is clinically significant.

FAQ

Is kisspeptin-10 approved or legal?: Kisspeptin-10 is not approved as a drug in any jurisdiction; it is investigational with ongoing clinical trials. It is not specifically listed on the WADA prohibited list by name, though WADA's S2 category covers substances with similar pharmacological action to prohibited peptide hormones; users in competitive sport should consult current WADA guidance. It is sold and used strictly as a research compound.
What does kisspeptin-10 do?: It binds GPR54/KISS1R receptors on hypothalamic GnRH neurons, triggering pulsatile GnRH release, which then stimulates LH and FSH from the pituitary, and ultimately testosterone (men) or oestradiol/progesterone (women) from the gonads. Loss-of-function GPR54 mutations in humans abolish puberty entirely, confirming the pathway is essential for reproductive axis function.
What is kisspeptin-10's half-life and why does it matter?: Approximately 4 minutes in human plasma (IV). This is very short — Kp-10 is undetectable by around 10 minutes. Clinical research protocols therefore use continuous IV infusion (typically 1.5 μg/kg/h for 9–12 hours) or frequent dosing rather than single bolus injections for sustained effects. Community subcutaneous protocols face different bioavailability and absorption dynamics not studied in published literature.
What is the human evidence?: Multiple clinical pharmacology studies have been published, primarily from Imperial College London. These demonstrate dose-dependent LH and testosterone rises in healthy men, phase-dependent LH responses in women, and restoration of gonadotropin pulsatility in patients with hypogonadotropic hypogonadism or hyperprolactinemia-induced amenorrhea. These are small, short-duration academic studies — not Phase 3 trials. No approved indication exists.
Is kisspeptin-10 safe?: Short-term clinical pharmacology studies in more than 150 combined human exposures have reported no serious adverse events and stable safety monitoring parameters. Mild events (nausea, headache) were rare and comparable to placebo frequency. Long-term safety, effects with chronic use, or safety of community subcutaneous protocols have not been studied. It is not recommended for unsupervised human use.
How does kisspeptin-10 compare to kisspeptin-54?: Both isoforms are GPR54 agonists with identical binding pharmacology at the receptor. Kp-54 has a plasma half-life of approximately 32 minutes versus approximately 4 minutes for Kp-10, and penetrates the blood-brain barrier far more effectively, directly activating a much higher proportion of GnRH neurons after peripheral dosing. Kp-54 is more potent per mole in vivo for this reason. Kp-10's short half-life makes it more tractable for controlled research protocols but may limit subcutaneous utility.

References

All content is for research and educational use only and is not medical advice. Products are sold for laboratory research only and are not for human consumption.